Hengehold Capital Management buys $1,971,163 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Hengehold Capital Management scooped up 95 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 31,086 shares of AbbVie Inc which is valued at $1,971,163.AbbVie Inc makes up approximately 0.62% of Hengehold Capital Management’s portfolio.

Other Hedge Funds, Including , Stewart Patten Co reduced its stake in ABBV by selling 595 shares or 3.67% in the most recent quarter. The Hedge Fund company now holds 15,634 shares of ABBV which is valued at $991,352. AbbVie Inc makes up approx 0.19% of Stewart Patten Co’s portfolio.Benjamin F. Edwards Company boosted its stake in ABBV in the latest quarter, The investment management firm added 411 additional shares and now holds a total of 9,207 shares of AbbVie Inc which is valued at $596,337. AbbVie Inc makes up approx 0.11% of Benjamin F. Edwards Company’s portfolio.New England Research Management reduced its stake in ABBV by selling 3,100 shares or 16.66% in the most recent quarter. The Hedge Fund company now holds 15,508 shares of ABBV which is valued at $960,255. AbbVie Inc makes up approx 0.84% of New England Research Management’s portfolio.

AbbVie Inc opened for trading at $63.57 and hit $63.9 on the upside on Wednesday, eventually ending the session at $63.41, with a gain of 0.14% or 0.09 points. The heightened volatility saw the trading volume jump to 75,02,821 shares. Company has a market cap of $102,557 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.